One example is lebrikizumab, a high-affinity anti-IL13 that has been shown to have efficacy in a phase 2b study of moderate to severe atopic dermatitis in adults and may be a candidate for future studies in food allergy [46]. This evidence concerns the gene IL13 and atopic eczema.